Emergence of rifampicin-resistant staphylococci on the skin and nose of rifampicin-treated patients with an orthopaedic-device-related infection
Alexandra Wallimann, Yvonne Achermann, C D Ferris, Mario Morgenstern, Martin Clauss, Vincent A. Stadelmann, Hannes A. Rüdiger, Liam O’Mahony, et al. (9 authors)
Journal of Bone and Joint Infection · 2024-07
Abstract
Rifampicin is a key antibiotic in the treatment of staphylococcal biofilm infections. In this pilot study, we found that patients who received rifampicin for treatment of an orthopaedic-device-related infection (ODRI) were colonized with rifampicin-resistant staphylococci during treatment and this persisted for up to 2 months after cessation of treatment.
MeSH terms
- Rifampicin
- Medicine
- Nose
- Dermatology
- Internal medicine
- Surgery